详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, #37 Guo Xue Xiang Street, Chengdu 610041, China [2]Sichuan University, Chengdu, China

出处：

DOI：

ISSN：

关键词： High risk Maintenance Myeloma Network meta-analysis Real-world study

摘要：

Although the significant strides in novel therapeutic approaches have prolonged the survival of multiple myeloma (MM) patients, the unfavorable prognosis of cytogenetically high-risk newly diagnosed MM (NDMM) remains intractable with the lack of consensus regarding the choice of maintenance regimens. Therefore, this study was initiated with the aim of examining the effectiveness of various maintenance treatments for this group of patients in jeopardy. Overall, 17 studies with 1937 high-risk NDMM patients were included in the network meta-analysis. Combination therapies involving novel drugs presented encouraging prospects in the maintenance phase, while the patients and circumstances for the application of different regimens still needed to be further distinguished and clarified. To investigate the current status of maintenance therapy of high-risk NDMM patients in clinical practice, a real-world cohort of high-risk NDMM was retrospectively incorporated 80 patients with lenalidomide maintenance and 53 patients with bortezomib maintenance, presenting the median PFS of 31.7 months and 30.4 months, respectively (p = 0.874, HR = 0.966, 95% CI: 0.628-1.486). Collectively, this study illuminated the present constraints of conventional approaches during the maintenance phase for high-risk NDMM patients while highlighting the future potential associated with enhanced regimens integrating novel medications.© 2024. The Author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

最新[2023]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, #37 Guo Xue Xiang Street, Chengdu 610041, China [2]Sichuan University, Chengdu, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China [2]Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China [3]Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study [4]Effectiveness and Safety of REBACIN as a Non-invasive Intervention for Persistent High-Risk Human Papillomavirus Infection: A Real-World Prospective Multicenter Cohort Study [5]Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China [6]A real-world, patient-reported outcomes study in patients with platinum-sensitive recurrent ovarian cancer receiving long-term maintenance therapy with niraparib [7]Prospetive study of thalidomide maintenance therapy in high-risk diffuse large B-cell lymphoma. [8]NETWORK META-ANALYSIS OF EFFICACY OF PEMETREXED- OR BEVACIZUMAB-BASED REGIMENS IN FIRST-LINE AND MAINTENANCE TREATMENT FOR ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER [9]Artificial Intelligence-Based Psoriasis Severity Assessment: Real-world Study and Application [10]Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study.